西立伐他汀降脂治疗及对血小板活化功能、胰岛素抵抗的影响

Effects of cerivastatin on platelet activity and insulin resistance in patients with primary hypercholesterolemia

目的 :探讨西立伐他汀对高胆固醇血症患者血脂、血小板活化功能、胰岛素抵抗 (IR)的干预作用。方法 :对 88例高胆固醇血症患者用西立伐他汀治疗 4～ 8wk,治疗前后观察血小板颗粒膜蛋白 (GMP- 140 )、空腹血糖 (FPG)、空腹胰岛素 (FINS)、总胆固醇 (TC)、高密度脂蛋白 -胆固醇 (HDL- C)、低密度脂蛋白 -胆固醇 (L DL- C)、三酰甘油 (TG) ,并计算胰岛素敏感指数 (ISI)。结果 :西立伐他汀能有效降低 FBG、FINS、L DL- C、TC、TG、GMP- 140 ,升高 ISI(P<0 .0 5 ) ,但对 HDL- C无显著变化 (P>0 .0 5 )。结论 :西立伐他汀治疗高胆固醇血症或混合性高脂血症患者 ,在调脂的同时 ,可抑制血小板活性 。

AIM: To study the effects of cerivastatin on insulin sensitivity, platelet activity. plasma lipids patients with primary hypercholesterolemia. METHODS: Eighty eight patients with primary hyper cholesterolemia were given cerivastatin for an average period of 4 wk and compared with the pretreatment in thrombocytic granule membrane protein(GMP 140), fasting plasma glucose(FPG), fasting serum insulin (FINS), total cholesterol (TC), high density lipoprotein cholesterol (HDL C); low density lipoprotein cholesterol (LDL C), and triglycerides (TG) and insulin sensitive index (ISI). RESULTS: The results showed that cerivastatin can reduce GMP 140, FPG、FINS、TC、TG 、 LDL C and improve insulin sensitive index ( P <0 05), but had no effects on HDL C ( P >0 05). CONCLUSION: The results suggest that lipid lowering therapy with cerivastatin has an additional effect on inhibiting the platelet activity and improving the insulin resistance.